Christobel Selecky Sells 25,000 Shares of ImmunityBio (NASDAQ:IBRX) Stock

ImmunityBio, Inc. (NASDAQ:IBRX) Director Christobel Selecky sold 25,000 shares of the business’s stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $10.00, for a total value of $250,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Christobel Selecky also recently made the following trade(s):

• On Tuesday, January 20th, Christobel Selecky sold 25,000 shares of ImmunityBio stock. The stock was sold at an average price of $7.51, for a total transaction of $187,750.00.
• On Friday, January 16th, Christobel Selecky sold 50,000 shares of ImmunityBio stock. The stock was sold at an average price of $5.00, for a total transaction of $250,000.00.

ImmunityBio Stock Down 17.4%

Shares of IBRX opened at $9.54 on Thursday. The stock has a market capitalization of $9.81 billion, a P/E ratio of -25.11 and a beta of 0.16. ImmunityBio, Inc. has a twelve month low of $1.83 and a twelve month high of $12.43. The firm has a fifty day simple moving average of $4.97 and a two-hundred day simple moving average of $3.28.

ImmunityBio (NASDAQ:IBRX) last released its quarterly earnings data on Monday, March 2nd. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02. The firm had revenue of $38.29 million during the quarter. Sell-side analysts expect that ImmunityBio, Inc. will post -0.92 EPS for the current fiscal year.

Institutional Trading of ImmunityBio

A number of hedge funds have recently modified their holdings of IBRX. Slow Capital Inc. bought a new stake in shares of ImmunityBio during the third quarter valued at approximately $25,000. Truist Financial Corp purchased a new stake in ImmunityBio during the 3rd quarter valued at $27,000. Swiss Life Asset Management Ltd purchased a new stake in ImmunityBio during the third quarter valued at $27,000. WealthPlan Investment Management LLC purchased a new position in ImmunityBio in the fourth quarter worth about $27,000. Finally, Diversify Advisory Services LLC bought a new stake in shares of ImmunityBio during the 2nd quarter valued at about $27,000. Institutional investors own 8.58% of the company’s stock.

Analyst Upgrades and Downgrades

IBRX has been the topic of a number of recent analyst reports. HC Wainwright lifted their price objective on ImmunityBio from $10.00 to $15.00 and gave the stock a “buy” rating in a research report on Monday. D. Boral Capital reaffirmed a “buy” rating and issued a $23.00 price target on shares of ImmunityBio in a research note on Monday. BTIG Research lifted their price target on shares of ImmunityBio from $6.00 to $9.00 and gave the company a “buy” rating in a report on Thursday, January 22nd. The Goldman Sachs Group reaffirmed a “buy” rating on shares of ImmunityBio in a research report on Monday. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of ImmunityBio in a research note on Monday, December 29th. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, ImmunityBio currently has a consensus rating of “Moderate Buy” and a consensus target price of $12.60.

More ImmunityBio News

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: ANKTIVA commercial adoption drove a multi‑hundred percent revenue increase, the headline catalyst for the recent rally — investors are treating this as evidence sales are scaling. Read More.
• Positive Sentiment: Multiple outlets report ~600–700% YoY revenue growth attributed to ANKTIVA uptake, reinforcing momentum and driving buying interest. Read More.
• Positive Sentiment: Regulatory/approval expansions and new commercial partnerships for ANKTIVA broaden the company’s global market opportunity—supports multi‑region revenue upside. Read More.
• Positive Sentiment: Q4 results beat consensus (smaller EPS loss and stronger revenue), which validated the commercial story in the near term and triggered bullish analyst notes. Read More.
• Neutral Sentiment: Analysis pieces highlight a disconnect between clinical progress, long‑term fundamentals and extreme short‑term price moves — useful context for risk/reward but not an immediate catalyst. Read More.
• Neutral Sentiment: Analysts (including HC Wainwright) kept bullish long‑term targets while adjusting near‑term EPS — supports a multi‑year upside thesis but adds short‑term uncertainty. Read More.
• Negative Sentiment: Insider selling: Director Barry J. Simon and others sold significant blocks in recent days, which can signal profit‑taking and weigh on sentiment. Read More.
• Negative Sentiment: Company remains unprofitable and consensus still forecasts a net loss for the current year — valuation and execution risks remain if commercial growth stalls. Read More.

ImmunityBio Company Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.